排序方式: 共有64条查询结果,搜索用时 171 毫秒
41.
该年度报告涉及2013 年最新上市的56 种新药及生物制品,包括20 种新孤儿药和10 种全新药物,以及获得美国FDA“新突破药物”称号的前3 名药物。此外,该年度报告还讨论了30 种重要的延伸性新药(新适应证、新剂型和现有药物的新复方),以及19 种年内首次获批但在该报告结束时尚未上市的新药。 相似文献
42.
Dongheon Lee Dongin Kim Yu Bin Choi Kyungjae Kang Eun-Sil Sung Jin-Hyung Ahn 《MABS-AUSTIN》2016,8(5):892-904
Several angiogenesis inhibitors targeting the vascular endothelial growth factor (VEGF) signaling pathway have been approved for cancer treatment. However, VEGF inhibitors alone were shown to promote tumor invasion and metastasis by increasing intratumoral hypoxia in some preclinical and clinical studies. Emerging reports suggest that Delta-like ligand 4 (Dll4) is a promising target of angiogenesis inhibition to augment the effects of VEGF inhibitors. To evaluate the effects of simultaneous blockade against VEGF and Dll4, we developed a bispecific antibody, HD105, targeting VEGF and Dll4. The HD105 bispecific antibody, which is composed of an anti-VEGF antibody (bevacizumab-similar) backbone C-terminally linked with a Dll4-targeting single-chain variable fragment, showed potent binding affinities against VEGF (KD: 1.3 nM) and Dll4 (KD: 30 nM). In addition, the HD105 bispecific antibody competitively inhibited the binding of ligands to their receptors, i.e., VEGF to VEGFR2 (EC50: 2.84 ± 0.41 nM) and Dll4 to Notch1 (EC50: 1.14 ± 0.06 nM). Using in vitro cell-based assays, we found that HD105 effectively blocked both the VEGF/VEGFR2 and Dll4/Notch1 signaling pathways in endothelial cells, resulting in a conspicuous inhibition of endothelial cell proliferation and sprouting. HD105 also suppressed Dll4-induced Notch1-dependent activation of the luciferase gene. In vivo xenograft studies demonstrated that HD105 more efficiently inhibited the tumor progression of human A549 lung and SCH gastric cancers than an anti-VEGF antibody or anti-Dll4 antibody alone. In conclusion, HD105 may be a novel therapeutic bispecific antibody for cancer treatment. 相似文献
43.
44.
该年度报告涉及2013 年最新上市的56 种新药及生物制品,包括20 种新孤儿药和10 种全新药物,以及获得美国FDA“新突破药物”称号的前3 名药物。此外,该年度报告还讨论了30 种重要的延伸性新药(新适应证、新剂型和现有药物的新复方),以及19 种年内首次获批但在该报告结束时尚未上市的新药。 相似文献
45.
Sarah K. Madden Albert Perez‐Riba Laura S. Itzhaki 《Protein science : a publication of the Protein Society》2019,28(4):738-745
Peptide display approaches, in which peptide epitopes of known binding activities are grafted onto stable protein scaffolds, have been developed to constrain the peptide in its bioactive conformation and to enhance its stability. However, peptide grafting can be a lengthy process requiring extensive computational modeling and/or optimisation by directed evolution techniques. In this study, we show that ultra‐stable consensus‐designed tetratricopeptide repeat (CTPR) proteins are amenable to the grafting of peptides that bind the Kelch‐like ECH‐associated protein 1 (Keap1) onto the loop between adjacent repeats. We explore simple strategies to optimize the grafting process and show that modest improvements in Keap1‐binding affinity can be obtained by changing the composition of the linker sequence flanking either side of the binding peptide. 相似文献
46.
《MABS-AUSTIN》2013,5(4):957-967
Antibody combination therapeutics (ACTs) are polyvalent biopharmaceuticals that are uniquely suited for the control of complex diseases, including antibiotic resistant infectious diseases, autoimmune disorders and cancers. However, ACTs also represent a distinct manufacturing challenge because the independent manufacture and subsequent mixing of monoclonal antibodies quickly becomes cost prohibitive as more complex mixtures are envisioned. We have developed a virus-free recombinant protein expression platform based on adeno-associated viral (AAV) elements that is capable of rapid and consistent production of complex antibody mixtures in a single batch format. Using both multiplexed immunoassays and cation exchange (CIEX) chromatography, cell culture supernatants generated using our system were assessed for stability of expression and ratios of the component antibodies over time. Cultures expressing combinations of three to ten antibodies maintained consistent expression levels and stable ratios of component antibodies for at least 60 days. Cultures showed remarkable reproducibility following cell banking, and AAV-based cultures showed higher stability and productivity than non-AAV based cultures. Therefore, this non-viral AAV-based expression platform represents a predictable, reproducible, quick and cost effective method to manufacture or quickly produce for preclinical testing recombinant antibody combination therapies and other recombinant protein mixtures. 相似文献
47.
实验用生物样品在生物医学研究中有着广泛的应用.生物样品的微生物污染可危及实验动物设施的生物安全以及对动物实验研究造成负面影响.因此在将生物样品接种到啮齿类动物之前,要对其进行检测以确保无啮齿类动物传染性病原体的污染.因为检测技术和经济上的限制和局限性,不可能对所有的啮齿类动物传染性病原都进行检测.本文依据科学文献、笔者的经验以及专家的意见,尝试着去阐述如何建立一个有效可行的生物样品微生物污染检测计划.笔者建议对一些重要的微生物进行检测,并简要综述了选取这些微生物的理由即它们对科研、实验动物生物安全以及职业健康安全的影响. 相似文献
48.
2015 年全年美国 FDA 共批准 45 个新分子实体和新生物制品,本文列出了 2016 年可能获 FDA 批准的新药目录,并对具体批准日
期进行了预测。 相似文献
49.
Juan Wang Jinxiang Zhou Yogender K. Gowtham Sarah W. Harcum Scott M. Husson 《Biotechnology progress》2017,33(3):658-665
This contribution describes strategies to purify monoclonal antibodies from Chinese hamster ovary (CHO) cell culture supernatant using newly designed multimodal membranes (MMMs). The MMMs were used for the capture step purification of human IgG1 following a size‐exclusion desalting column to remove chaotropic salts that interfere with IgG binding. The MMM column attained higher dynamic binding capacity than a Protein A resin column at an equivalent residence time of 1 min. The two‐step MMM chromatography process achieved high selectivity for capturing hIgG1 from the CHO cell culture supernatant, though the desalting step resulted in product dilution. Product purity and host cell protein (HCP) level in the elution pool were analyzed and compared to results from a commercial Protein A column. The product purity was >98% and HCP levels were <20 ppm for both purification methods. In addition, hIgG1 could be eluted from the MMM chromatography column at neutral pH, which is important for limiting the formation of aggregates; although slow elution dilutes the product. Overall, this paper shows that MMMs are highly effective for capture step purification of proteins and should be considered when Protein A cannot be used, e.g., for pH sensitive mAbs or proteins lacking an Fc binding domain. © 2017 American Institute of Chemical Engineers Biotechnol. Prog., 33:658–665, 2017 相似文献
50.
Gwendolyn M Wilmes Kimberly L Carey Stuart W Hicks Hugh H Russell Jesse A Stevenson Paulina Kocjan Stephen R Lutz Rachel S Quesenberry Sergey V Shulga-Morskoy Megan E Lewis Ethan Clark Violetta Medik Anthony B Cooper Elizabeth E Reczek 《MABS-AUSTIN》2014,6(4):957-967
Antibody combination therapeutics (ACTs) are polyvalent biopharmaceuticals that are uniquely suited for the control of complex diseases, including antibiotic resistant infectious diseases, autoimmune disorders and cancers. However, ACTs also represent a distinct manufacturing challenge because the independent manufacture and subsequent mixing of monoclonal antibodies quickly becomes cost prohibitive as more complex mixtures are envisioned. We have developed a virus-free recombinant protein expression platform based on adeno-associated viral (AAV) elements that is capable of rapid and consistent production of complex antibody mixtures in a single batch format. Using both multiplexed immunoassays and cation exchange (CIEX) chromatography, cell culture supernatants generated using our system were assessed for stability of expression and ratios of the component antibodies over time. Cultures expressing combinations of three to ten antibodies maintained consistent expression levels and stable ratios of component antibodies for at least 60 days. Cultures showed remarkable reproducibility following cell banking, and AAV-based cultures showed higher stability and productivity than non-AAV based cultures. Therefore, this non-viral AAV-based expression platform represents a predictable, reproducible, quick and cost effective method to manufacture or quickly produce for preclinical testing recombinant antibody combination therapies and other recombinant protein mixtures. 相似文献